Koji Matsumoto

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

A study of an in vitro model for invasion of oral squamous cell carcinoma

Koji Matsumoto, Masaru Horikoshi, Koichi Rikimaru et al. · Journal of Oral Pathology and Medicine · 1989 · 86 citations

Stereocontrolled total synthesis of (−)-aspidophytine

Shinjiro Sumi, Koji Matsumoto, Hidetoshi Tokuyama et al. · Tetrahedron · 2003 · 70 citations

Pharmacology, Enantioselective Synthesis, Stereoselective Synthesis +1

Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)

Yukinori Ozaki, Junji Tsurutani, Toru Mukohara et al. · European Journal of Cancer · 2022 · 30 citations · Full text